Literature DB >> 28991707

Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.

Pedro Sánchez1, Virginia Meca-Lallana2, Antonio Barbosa3, Rafael Manzanares3, Itziar Palmí2, José Vivancos2.   

Abstract

BACKGROUND AND
OBJECTIVE: Tumefactive demyelinating lesions (TDLs) are large inflammatory lesions that can mimic tumors or other space-occupying lesions. Differential diagnosis and management of these lesions remain challenging for neurologists. We aim to review the clinico-radiological features of patients with TDLs, as well as their management.
METHODS: We performed a retrospective review of cases of TDLs treated in our center from January 2010 to February 2017. We reviewed the literature.
RESULTS: Out of 711 patients, we found 15 with TDLs (12 women and 3 men), with a mean age of TDL onset of 36years. Out of the 15 patients, 9 had TDLs as a first demyelinating event and 44% (4/15) of these converted to MS by McDonald 2010 criteria in a mean time of 8months (SD 3.10). Clinical presentation was polysymptomatic and the most common radiological findings included solitary lesions (66.66%), located primarily in the frontal (40%) or parietal (33%) lobes, showing mostly an infiltrative morphological pattern (50%) and an open-ring enhancement (43%). Multiple Sclerosis was the most common diagnosis (67%, 10/15). Acute treatment included steroids, plasmapheresis, rituximab and cyclophosphamide.
CONCLUSIONS: Prevalence of tumefactive demyelination in MS was higher than expected in MS patients, according to literature. Time to conversion to MS was significantly shorter than other published series. Clinical presentation was polysymptomatic and the most common radiological findings were isolated frontal lesions with an open-ring enhancement.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28991707     DOI: 10.1016/j.jns.2017.08.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.

Authors:  Mahboubeh Fereidan-Esfahani; Paul A Decker; Jeanette E Eckel Passow; Claudia F Lucchinetti; Eoin Patrick Flanagan; William Oliver Tobin
Journal:  Eur J Neurol       Date:  2021-12-09       Impact factor: 6.089

2.  Isolated Medullary Tumefactive Demyelination Masquerading as Tumor.

Authors:  Sushant Agarwal; Leve Joseph; Awad Kishore Pandit; Achal Srivastava; Ajay Garg
Journal:  Ann Indian Acad Neurol       Date:  2022-04-20       Impact factor: 1.714

3.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

4.  Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.

Authors:  Ayano Shima; Tsuyoshi Hamaguchi; Yasutake Tada; Masahito Yamada
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

5.  When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.

Authors:  Breanna Taylor; Mallika P Patel; Katherine B Peters
Journal:  CNS Oncol       Date:  2021-01-15

6.  Deep Learning With Data Enhancement for the Differentiation of Solitary and Multiple Cerebral Glioblastoma, Lymphoma, and Tumefactive Demyelinating Lesion.

Authors:  Yu Zhang; Kewei Liang; Jiaqi He; He Ma; Hongyan Chen; Fei Zheng; Lingling Zhang; Xinsheng Wang; Xibo Ma; Xuzhu Chen
Journal:  Front Oncol       Date:  2021-08-18       Impact factor: 6.244

7.  Progressive Tumefactive Demyelination as the Only Result of Extensive Diagnostic Work-Up: A Case Report.

Authors:  Pavel Štourač; Jan Kolčava; Miloš Keřkovský; Tereza Kopřivová; Leoš Křen; Josef Bednařík
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

8.  A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.

Authors:  Yuri Nakamura; Laura Gaetano; Takuya Matsushita; Altermatt Anna; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Lorena Bauer; Michael Amann; Koji Shinoda; Noriko Isobe; Ryo Yamasaki; Takahiko Saida; Ludwig Kappos; Jun-Ichi Kira
Journal:  J Neuroinflammation       Date:  2018-09-05       Impact factor: 8.322

9.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.